Nahorski S R, Barnett D B, Howlett D R, Rugg E L
Naunyn Schmiedebergs Arch Pharmacol. 1979 Jul;307(3):227-33. doi: 10.1007/BF00505938.
[3H]-(--)-Dihydroalprenolol ([3H]-DHA) binds to rat spleen membranes with a dissociation equilibrium constant (KD) of about 0.7 nM and a maximal number of binding sites of 272 fmoles x mg protein-1. Approximately 90% of the sites labelled by 1 nM [3H]-DHA possess classical properties of beta-adrenoceptors. The labelled ligand is stereospecifically displaced by the isomers of propranolol and the order of potency of agonists is: isoprenaline greater than adrenaline greater than noradrenaline. Highly selective beta 1 antagonists such as practolol and atenolol displaced [3H]-DHA from spleen membranes in a biphasic manner indicating the co-existence of beta 1 and beta 2 sites (30--35% beta 1; 65--70% beta 2) in this tissue. Support for this classification was provided by the binding of the beta 2 agonist procaterol to spleen membranes. This drug possessed high affinity only for those sites that have low affinity for the beta 1 selective agents. Chemical sympathectomy induced by chronic 6-hydroxydopamine administration did not alter the number or the pharmacological properties of beta-adrenoceptor binding sites. The results suggest that both beta 1 and beta 2 adrenoceptors are probably postsynaptic in spleen.
[3H] -(-)-二氢烯丙洛尔([3H] -DHA)与大鼠脾脏膜结合,解离平衡常数(KD)约为0.7 nM,最大结合位点数为272 fmol×mg蛋白-1。1 nM [3H] -DHA标记的位点中约90%具有β-肾上腺素能受体的经典特性。标记配体被普萘洛尔异构体立体特异性取代,激动剂的效力顺序为:异丙肾上腺素>肾上腺素>去甲肾上腺素。高度选择性的β1拮抗剂如醋丁洛尔和阿替洛尔以双相方式从脾脏膜中取代[3H] -DHA,表明该组织中存在β1和β2位点(30 - 35%为β1;65 - 70%为β2)。β2激动剂丙卡特罗与脾脏膜的结合为这种分类提供了支持。该药物仅对那些对β1选择性药物亲和力低的位点具有高亲和力。慢性给予6-羟基多巴胺诱导的化学交感神经切除术并未改变β-肾上腺素能受体结合位点的数量或药理学特性。结果表明,β1和β2肾上腺素能受体在脾脏中可能均位于突触后。